| __timestamp | Alnylam Pharmaceuticals, Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 13774000 |
| Thursday, January 1, 2015 | 60610000 | 22479000 |
| Friday, January 1, 2016 | 89354000 | 27388000 |
| Sunday, January 1, 2017 | 199365000 | 35610000 |
| Monday, January 1, 2018 | 382359000 | 49007000 |
| Tuesday, January 1, 2019 | 479005000 | 61139000 |
| Wednesday, January 1, 2020 | 588420000 | 68836000 |
| Friday, January 1, 2021 | 620639000 | 97592000 |
| Saturday, January 1, 2022 | 770658000 | 106903000 |
| Sunday, January 1, 2023 | 795646000 | 120998000 |
| Monday, January 1, 2024 | 975526000 |
Unleashing the power of data
In the competitive landscape of biotechnology, understanding spending patterns is crucial. Alnylam Pharmaceuticals and Vericel Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alnylam's SG&A expenses surged by approximately 1,700%, reflecting its aggressive growth strategy. In contrast, Vericel's expenses increased by about 780%, indicating a more conservative approach.
Alnylam's spending peaked in 2023, with expenses nearly doubling from 2018 to 2023. This trend underscores its commitment to expanding its market presence and investing in innovative therapies. Meanwhile, Vericel's steady increase in SG&A expenses highlights its focus on sustainable growth and operational efficiency. These patterns offer valuable insights into each company's strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Vericel Corporation
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Vericel Corporation
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Alnylam Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Vericel Corporation
Breaking Down SG&A Expenses: Alpine Immune Sciences, Inc. vs Vericel Corporation